Jubilant Pharmova Ltd
Jubilant Pharmova Ltd Q1 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q1 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Jubilant Pharmova Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Total Income for Q1’FY25 was Rs. EBITDA: Rs.
From Jubilant Pharmova Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Total Income for Q1’FY25 was Rs. 1,746 Cr, a 9% increase YoY.
- Segment revenues (Q1’FY25, YoY % increase):
- Radiopharma: Rs. 832 Cr (up from Rs. 691 Cr)
- Radiopharmaceuticals: Rs. 262 Cr (+28%)
- Radiopharmacies: Rs. 570 Cr (+17%)
- Allergy Immunotherapy: Rs. 168 Cr (+11%)
- CDMO Sterile Injectables: Rs. 324 Cr (+27%)
- Generics: Rs. 156 Cr (down 23%)
- CRDMO: Rs. 243 Cr (down YoY from Rs. 280 Cr)
- Volume and price increases primarily drove growth in Radiopharma and Allergy Immunotherapy.
- Outlook:
- Expect continued revenue growth momentum in FY25.
- CDMO Sterile Injectables Line 3 & 4 production to start in FY26 and FY28 with revenue potential of USD 160-180 million.
- New product launches planned (6-8 annually) in US and other international markets.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Spokane Sterile Injectables Expansion:
- Doubling capacity with state-of-the-art technology.
- Total investment: USD 285 million, partly funded (USD 149.6 million) by US Govt.
- Line 3 commercial production expected FY26; Line 4 in FY28.
- Revenue potential for Lines 3 & 4 combined: USD 160-180 million.
- Efforts underway to fill new capacity faster than industry average (3-4 years).
- Radiopharmacy Network Expansion:
- Planned investment: USD 50 million.
- Expand PET radiopharmacy network to 9 sites; total network to 52 sites in US.
- Fully operational by FY28 with expected RoCE >20%.
- Roorkee Solid Dosage Facility:
- Facility status changed from Salisbury, Maryland to Roorkee.
- Exports to US expected to increase gradually; supply to US market to start H2’FY25.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Pharmova Ltd's management said in earlier quarters
- Q4 FY24 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call →
- Q3 FY23 earnings call →
- Q2 FY23 earnings call →
- Q1 FY23 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q1 FY22 earnings call →
- Q4 FY21 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q1 FY25)
Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Key investor presentation takeaways from NG
- Shree Ganesh Remedies Ltd (Q1 FY25)
Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY
- Themis Medicare Ltd (Q1 FY25)
122.99 Cr, up 27.26% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q1 FY25 investor presentation — and how it ranks against sector
- Fermenta Biotech Ltd (Q1 FY25)
The Annual Standalone Financial Performance (Page 26) reports full-year FY24 operational revenue of INR 3,071 million, down 6.6% YoY from INR 3,289 million in…
Frequently Asked Questions
What were Jubilant Pharmova Ltd Q1 FY25 results?
Total Income for Q1’FY25 was Rs. EBITDA: Rs.
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Pharmova Ltd planning capital expenditure?
Spokane Sterile Injectables Expansion: - Doubling capacity with state-of-the-art technology.
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.